Business Details
18 Years
experience
Innovative MASH Therapeutics & Research Leadership
Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to advancing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease with significant unmet medical needs. Since our founding in 2008, we have pioneered research that led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH, marking a historic milestone in liver disease innovation. Our mission focuses on halting or reversing liver scarring (fibrosis) to prevent life-threatening complications such as cirrhosis, liver failure, and transplantation. With over 500 employees across the United States and Europe, our team combines deep scientific expertise with a relentless pursuit of innovation to transform care for MASH patients. Our leadership in clinical development is underscored by multiple Phase 3 trials, including the landmark MAESTRO-NASH study, which established our medication as a breakthrough therapy.We prioritize patient-centric solutions, guided by core values of accountability, collaboration, and scientific rigor. Our research targets the thyroid hormone receptor-beta (THR-) pathway, addressing the root causes of liver dysfunction through liver-directed therapies. By fostering a culture of innovation and inclusivity, we aim to expand treatment paradigms for diverse patient populations with high unmet needs. Our commitment to transparency and ethical practices ensures trust in all aspects of our operations, from clinical trials to patient support programs. As a fully integrated biopharma company, we continue to lead the fight against MASH, driven by the belief that no family should endure the devastation of advanced liver disease.
Services
MASH Therapeutics Development
Clinical Research Trials
Liver Disease Innovation
Patient Support Programs
Pharmaceutical Research
Details
- Year established: 2008
Highlights and features
- We developed the first FDA-approved treatment for MASH, a breakthrough in liver disease therapy.
- Our research targets the THR- pathway, addressing MASH's root causes through liver-directed therapies.
- We lead the largest clinical development program in MASH with multiple Phase 3 trials completed.
- Our team combines over a decade of MASH research expertise with a patient-first approach.
- We operate across the U.S. and Europe, serving diverse populations with high unmet medical needs.
Services
MASH Therapeutics Development
Our MASH therapeutics development focuses on liver-directed therapies targeting the thyroid hormone receptor-beta (THR-) pathway. This approach addresses metabolic dysfunction and fibrosis by restoring liver cell function and reducing inflammation. Our FDA-approved medication, resmetirom, represents the first breakthrough in MASH treatment, offering patients a solution to halt or reverse liver scarring before complications arise.
Clinical Research Trials
We conduct comprehensive clinical research trials, including the Phase 3 MAESTRO-NASH and MAESTRO-Cirrhosis studies, to evaluate treatment efficacy across MASH patient populations. These trials focus on noncirrhotic and cirrhotic patients, ensuring therapies address varying stages of liver disease. Our research prioritizes safety, tolerability, and long-term outcomes to expand treatment access for underserved populations.
Patient Support Programs
Our patient support programs provide resources for diagnosis, affordability, and education throughout the MASH treatment journey. We offer dedicated assistance for adverse event reporting, medication access, and clinical trial enrollment. These initiatives ensure patients receive personalized guidance and transparent information about treatment options and disease management.
Liver Disease Innovation
Liver disease innovation drives our exploration of novel treatment paradigms for MASH and related metabolic conditions. Our research spans preclinical studies to post-approval monitoring, leveraging over 15 years of expertise in liver biology. By focusing on mitochondrial dysfunction and lipid metabolism, we aim to develop therapies that improve liver health and patient outcomes globally.
Pharmaceutical Research
Pharmaceutical research at Madrigal centers on advancing THR- agonists like resmetirom through rigorous clinical and regulatory pathways. Our work bridges discovery science with commercialization, ensuring therapies meet FDA standards for safety and efficacy. This process includes biomarker analysis, trial design optimization, and partnerships to accelerate drug delivery for MASH patients.
People
Rebecca Taub
Founder and Director of Research and Clinical Development
Dr. Taub pioneered MASH research by identifying THR- agonism as a therapeutic strategy. She founded Madrigal in 2008 and led the development of resmetirom, the first FDA-approved MASH treatment. Her work focuses on liver biology and metabolic disease.
Bill Sibold
Chief Executive Officer
Bill Sibold joined Madrigal in 2023 to lead its transition into a fully integrated biopharma company. He oversees commercialization of resmetirom and expansion of the executive team. His leadership emphasizes patient access and innovation in liver disease treatment.
Stephen Harrison
Principal Investigator of MAESTRO-NASH Study
Dr. Harrison was a leading hepatologist and principal investigator for the MAESTRO-NASH trial. His contributions to MASH research advanced understanding of fibrosis progression and treatment outcomes. He passed away in 2024, leaving a legacy in liver disease innovation.
Kim
Patient Advocate
Kim advocates for MASH patients, emphasizing the need for early diagnosis and accessible treatments. Her work highlights the personal impact of liver disease and supports community education initiatives to raise awareness about MASH risks.
Kerry
Patient Advocate
Kerry collaborates with healthcare providers to improve MASH patient care. She focuses on bridging gaps between clinical research and patient needs, ensuring therapies address real-world challenges faced by individuals with liver disease.
Questions
What is Madrigal Pharmaceuticals' primary focus?
We specialize in developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease with high unmet medical need.
What is MASH?
MASH is a serious liver condition caused by metabolic dysfunction, leading to fat accumulation, inflammation, and scarring (fibrosis) that can progress to cirrhosis or liver failure.
What treatments does Madrigal offer for MASH?
We developed resmetirom, the first FDA-approved treatment for MASH, which targets liver scarring and fibrosis through THR-β agonism.
How can patients access Madrigal's therapies?
Patients can access resmetirom through healthcare providers in the U.S., with support programs available for affordability and clinical trial enrollment.
Does Madrigal conduct clinical trials?
Yes, we run Phase 3 trials like MAESTRO-NASH and MAESTRO-Cirrhosis to evaluate treatment efficacy across MASH patient populations.
How does Madrigal support patient safety?
We monitor adverse events, maintain rigorous clinical trial standards, and provide resources for reporting medication-related concerns.
